Utah Ketamine Authority

Ketamine and Trauma

Ketamine and The Treatment of Trauma

Trauma results from exposure to an event or series of events that are emotionally disturbing or life-threatening. Symptoms of trauma may include: shock, irritability, difficulty concentrating, guilt and shame, and feeling disconnected or numb. Trauma can negatively impact relationships and can increase the risk of chronic health conditions.

Trauma requires treatment tailored to the specific needs and symptoms of the client. Therapy for clients with trauma focuses on rebuilding hope for the future, teaching healthy and sustainable coping skills, and improving symptoms such as: nightmares, agitation, flashbacks, anxiety, and depression. Our counselors are trained in Positive Psychology, Cognitive Behavioral Therapy (CBT), and Acceptance and Commitment Therapy (ACT) and ready to assist clients in healing.

Integrated Ketamine Assisted Psychotherapy (IKAP) is also a treatment option for client’s struggling with trauma. IKAP is the combination of psychotherapy and an IV ketamine infusion. This process invites neuroplasticity (the ability to change and grow) within the brain’s neural connections. This allows clients the ability to process trauma, embrace change, and focus on hope for the future.


Resources and Relevant Studies – Ketamine Facts

Subcutaneous Ketamine in Depression: A Systematic Review

Ketamine has been studied and used for psychiatric purposes for over 20 years (1). Its rapid and robust antidepressant effect has been reproduced across numerous studies by significantly decreasing the severity of depression, achieving substantial rates of response and remission even for patients that were non-responsive to previous treatments.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193034

Ketamine as a promising prototype for a new generation of rapid-acting antidepressant

In the early 1990s, researchers conducting preclinical studies found that NMDA-R antagonists showed promising antidepressant qualities.78 Later in the 1990s, in a pilot study in patients with severely treatment-resistant depression, we discovered that a single subanesthetic dose of ketamine had striking, robust, rapid antidepressant effects within 4 h of intravenous administration.9 This finding has since been well replicated in multiple controlled trials,1011 underscoring the rationale of targeting the glutamatergic system and the feasibility of developing truly novel rapid-acting antidepressant agents.1213 These noticeable rapid antidepressant effects have also been reported in patient groups known to respond poorly to traditional antidepressant interventions, such as those with bipolar depression, anxious depression, and patients who are treatment resistant to electroconvulsive therapy (ECT).1417 In addition, ketamine showed efficacy in rapidly reducing suicidal ideation within hours of administration.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412785/